Timolol - NDSRI's
References
FAQ's
References
- Wasson, Burton K., 4-(3-Secondary Amino-2-Hydroxy-Proxy) 1 2 5-Thiadiazoles, Frosst, Charles E., and Co., US3655663A, April 11, 1972
- Mohamed, M. E.; Tawakkol, M. S.; Aboul-Enein, H. Y., Spectrophotometric determination of timolol and other β-adrenergic blocking drugs and in pharmaceutical preparations, Spectroscopy Letters, Volume: 15, Issue: 8, Pages: 609-21, 1982
Frequently Asked Questions
What are the common impurities that can occur during the manufacturing of Timolol?
Common impurities that may occur during the manufacturing of Timolol include truncated or modified peptide chains, residual solvents, heavy metals, and related substances.
How are Timolol impurities identified and quantified during the manufacturing process?
Timolol impurities are identified and quantified during manufacturing using techniques like UPLC. These techniques help determine the type and quantity of impurities in the sample.
Can impurities in Timolol impact its bioavailability?
Timolol impurities can affect its bioavailability and potentially lead to reduced absorption or altered pharmacokinetics.
What measures prevent the formation of Timolol impurities during drug storage?
Timolol is stored under carefully controlled conditions, including temperature and humidity control, to prevent the formation of impurities.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.